摘要
目的:本研究观察复方皂矾丸联合环孢素、雄激素治疗慢性再生障碍性贫血(CAA)的临床疗效及其对骨髓微血管密度(MVD)、血管内皮生长因子(VEGF)的影响。方法:将我院76例确诊的CAA随机分为2组:治疗组1采用环孢素、雄激素;治疗组2在组1的基础上加用复方皂矾丸,两治疗组于治疗前及治疗后半年检测骨髓MVD和VEGF水平。20例正常骨髓蜡块作对照组。结果:CAA患者治疗前骨髓MVD、VEGF表达较正常对照组明显下降(P<0.01),治疗后两者均较治疗前升高(P<0.01);治疗组2治愈率、缓解率(44.7%)较治疗组1(15.8%)升高,差异有统计学意义(P<0.05);两治疗组治疗前骨髓MVD、VEGF阳性细胞百分率无差异,治疗组2治疗后骨髓MVD、VEGF表达均较治疗前增高,且较治疗组1治疗后进一步升高。结论:复方皂矾丸联合环孢素加雄激素治疗CAA能进一步提高骨髓MVD、VEGF水平,获得较好临床疗效。
Objective: To investigate the clinical efficacy of compound Zaofan pill combined with cyclosporine and androgen for treatment of patients with chronical aplastic anemia ( CAA), and its effect on bone marrow microvessel density (MVD) and vascular endothelial growth factor (VEGF) of CAA patients. Methods: A total of 76 cases of CAA were randomly divided into group 1 and group 2, among them the group 1 (38 cases)was treated with cyclosporine and androgen alone, while the group 2 (38 cases ) was treated with compound Zaofan pill combined with cyclosporine and androgen. Samples of 20 cases with normal bone marrow were used as controls. The clinical effects of each groups were observed, and the mean bone marrow MVD and VEGF levels were detected before and after half a year's treatment. Results: The mean bone marrow MVD and VEGF levels in CAA group before treatment were significantly lower than that in normal control group, but bone marrow MVD and VEGF levels in 2 groups significantly increased after treatment. Group 1 showed the cure and response rate of 15.8%, while group 2 showed the cure and response rate of 44.7%, there was significant difference between the two groups ( P 〈 0.05 ) ). There was no significant difference of bone marrow MVD and VEGF expression before treatment between group 1 and group 2. After treatment, bone marrow MVD and VEGF expression of group 2 were significantly higher than pre-treatment, moreover the bone marrow MVD and VEGF expression in group 2 were significantly higher than that in group 1. Conclusions: The compound Zaofan pill combined with cyclosporine and androgen can obviously increase the levels of MVD and VEGF in bone marrow, and improve the efficacy of treatment in CAA patients.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2015年第2期477-480,共4页
Journal of Experimental Hematology